<DOC>
	<DOCNO>NCT01562301</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Anvirzel ( Nerium Oleander ) give lung cancer patient receive standard therapy carboplatin docetaxel . Researchers also want learn effect Nerium Oleander may combination carboplatin docetaxel .</brief_summary>
	<brief_title>Sublingual Anvirzel Advance Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Study Drug Administration : If eligible agree take part study , assign dose level nerium oleander base join study . Up 5 dose level nerium oleander test . At least 3 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose nerium oleander find . You take nerium oleander mouth place tongue . You hold nerium oleander tongue 3 minute swallow . It important hold nerium oleander tongue 3 full minute . Holding tongue 3 minute swallow help body take high amount drug receive . If hold nerium oleander tongue le 3 minute , body receive much study drug may possibly benefit much . You take nerium oleander 3 time day participate study . Nerium oleander take empty stomach least 15 minute large meal , help body take much drug possible . Study Visits : Each chemotherapy cycle 21 day . Each week study , complete questionnaire symptom may . It take 5 minute complete time . Cycle 1 : On Day -7 ( 7 day start chemotherapy ) : - You complete questionnaire physical mental health . It take 5 minute complete . - Blood ( 2 teaspoon time ) drawn 6 time 8 hour pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point . - Blood ( 6 teaspoon ) drawn learn study drug reduce inflammation . - Blood ( 2 teaspoon ) draw test effect study drug immune system . On Day -6 , blood ( 2 teaspoon time ) draw 1 time PK test . On Day 1 ( day start chemotherapy ) : - You ask symptom may drug may take . - You physical exam , include measurement weight vital sign . - Your performance status record . - You complete questionnaire physical mental health . - Blood ( 1 teaspoon ) drawn routine test . - Blood ( 2 teaspoon time ) drawn 6 time 8 hour PK test . - Blood ( 6 teaspoon ) drawn learn study drug reduce inflammation . - Blood ( 2 teaspoon ) draw test effect study drug immune system . - You EKG . On Day 2 : - Blood ( 2 teaspoon ) draw PK test . - Blood ( 6 teaspoon ) drawn learn study drug reduce inflammation . - Blood ( 2 teaspoon ) draw test effect study drug immune system . On Day 8 ( +/- 2 day ) : - Blood ( 6 teaspoon ) drawn learn study drug reduce inflammation . - Blood ( 2 teaspoon ) draw test effect study drug immune system . On Day 1 Cycles 2-3 : - You ask symptom may drug may take . - You physical exam , include measurement weight vital sign . - Blood ( 1 teaspoon ) drawn routine test . - Your performance status record . - You EKG . - You complete questionnaire physical mental health . - On Day 1 Cycle 3 , CT scan check status disease . On Day 1 Cycle 4 : - You ask symptom may drug may take . - You physical exam , include measurement weight vital sign . - You complete questionnaire physical mental health . - Blood ( 1 teaspoon ) drawn routine test . - Your performance status record . - You EKG . - Blood ( 2 teaspoon time ) drawn 6 time 8 hour PK test . - Blood ( 6 teaspoon ) drawn learn study drug reduce inflammation . - Blood ( 2 teaspoon ) draw test effect study drug immune system . On Day 2 Cycle 4 : - Blood ( 2 teaspoon ) draw PK test . On Day 8 Day 21 Cycle 4 ( +/- 2 day ) : - Blood ( 6 teaspoon ) drawn learn study drug reduce inflammation . - Blood ( 2 teaspoon ) draw test effect study drug immune system . Length Study : You may continue take study drug long doctor think best interest 4 cycle . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . End-of-Dosing Visit : After last dose study drug , return clinic . The following test procedure perform : - You ask symptom may drug may take . - You physical exam , include measurement weight vital sign . - Blood ( 1 teaspoon ) drawn routine test . - You EKG . - You CT scan check status disease . - You complete questionnaire . Follow-Up Visit : About 30 day last dose study drug , follow test procedure perform : - You ask symptom may drug may take . - You physical exam , include measurement weight vital sign . - Blood ( 1 teaspoon ) drawn routine test . - You EKG . - You complete questionnaire . This investigational study . Nerium oleander FDA approve commercially available . Its use study consider investigational . Up 36 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm diagnose advanced nonsmall cell lung cancer ( Stage IIIB IV ) schedule receive four cycle carboplatin docetaxel chemotherapy . 2 . Newly diagnose previously treat patient NSCLC . Previously treat patient allow previous chemotherapy treatment NSCLC . 3 . Age &gt; 18 year 4 . ECOG performance status &lt; =2 ( Karnofsky &gt; = 60 % ) 5 . Life expectancy great 6 month 6 . Patients must normal organ marrow function define : leukocyte &gt; = 3,000/mcL absolute neutrophil count &gt; = 1,500/mcL platelet &gt; = 100,000/mcL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; = 2.5 X institutional upper limit normal creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m2 patient creatinine level institutional normal 7 . Negative serum urine pregnancy test woman childbearing potential 8 . Scheduled begin carboplatin docetaxel chemotherapy next 30 day 9 . The effect Anvirzel develop human fetus unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 10 . Ability understand willingness sign write informed consent document 1 . Patients receive investigational agent 2 . History allergic reaction attribute compound similar chemical biologic composition cardiac glycosides 3 . Patients receive medication substance inhibitor inducer CYP 3A4 ineligible 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 5 . Pregnant breastfeed woman 6 . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction Anvirzel . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . 7 . Uncontrolled significant cardiovascular disease , include : • Myocardial infarction within 6 month • Uncontrolled angina within 6 month • Newly diagnose congestive heart failure within 6 month , define NYHCII currently uncontrolled congestive heart failure • Diagnosed suspected congenital long QT syndrome • Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , WolffParkinsonWhite ( WPW ) syndrome , torsade de pointes ) . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) . If automate reading prolong ( i.e. , &gt; 450 msec ) , EKG manually overread • Any history second third degree heart block • Heart rate &lt; 50 beats/minute sustain heart rate &gt; 110 preentry electrocardiogram • Newly diagnose atrial fibrillation within 6 month currently uncontrolled atrial fibrillation • Uncontrolled hypertension define sustain blood pressure &gt; /= 140/90mm Hg 8 . Current use pacemaker 9 . Patients use schedule use bevacizumab study period 10 . Current use cardiac glycoside</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Anvirzel</keyword>
	<keyword>nerium oleander</keyword>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>